Search Results

There are 28290 results for: content related to: Distribution and excretion of fluoxetine and norfluoxetine in human milk

  1. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 71, Issue 4, August 2004, Pages: 193–280, Ronald N. Hines, Jane Adams, Germaine M. Buck, Willem Faber, Joseph F. Holson, Sandra W. Jacobson, Martin Keszler, Kenneth McMartin, Robert Taylor Segraves, Lynn T. Singer, I. Glenn Sipes and Paige L. Williams

    Version of Record online : 23 AUG 2004, DOI: 10.1002/bdrb.20014

  2. You have free access to this content
    Fluoxetine versus other types of pharmacotherapy for depression

    Intervention Review

    The Cochrane Library

    Laura R Magni, Marianna Purgato, Chiara Gastaldon, Davide Papola, Toshi A Furukawa, Andrea Cipriani and Corrado Barbui

    Published Online : 17 JUL 2013, DOI: 10.1002/14651858.CD004185.pub3

  3. You have free access to this content
    Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding

    British Journal of Clinical Pharmacology

    Volume 61, Issue 2, February 2006, Pages: 155–163, John Kim, K. Wayne Riggs, Shaila Misri, Nancy Kent, Tim F. Oberlander, Ruth E. Grunau, Colleen Fitzgerald and Dan W. Rurak

    Version of Record online : 28 NOV 2005, DOI: 10.1111/j.1365-2125.2005.02538.x

  4. Fluoxetine Potentiation of Omega-3 Fatty Acid Antidepressant Effect: Evaluating Pharmacokinetic and Brain Fatty Acid-Related Aspects in Rodents

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 10, October 2014, Pages: 3316–3325, Carlos Horacio Laino, Pilar Garcia, María Fernanda Podestá, Christian Höcht, Nora Slobodianik and Analía Reinés

    Version of Record online : 29 AUG 2014, DOI: 10.1002/jps.24123

  5. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation

    Clinical Pharmacology & Therapeutics

    Volume 73, Issue 4, April 2003, Pages: 330–337, Tuija Heikkinen, Ulla Ekblad, Pertti Palo and Kari Laine

    Version of Record online : 25 APR 2003, DOI: 10.1016/S0009-9236(02)17634-X

  6. You have free access to this content
    Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine

    British Journal of Pharmacology

    Volume 149, Issue 5, November 2006, Pages: 481–489, S Rajamani, L L Eckhardt, C R Valdivia, C A Klemens, B M Gillman, C L Anderson, K M Holzem, B P Delisle, B D Anson, J C Makielski and C T January

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706892

  7. You have free access to this content
    The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)-induced degeneration of 5-HT nerve endings in rat brain

    British Journal of Pharmacology

    Volume 134, Issue 1, September 2001, Pages: 46–57, V Sanchez, J Camarero, B Esteban, M J Peter, A R Green and M I Colado

    Version of Record online : 2 FEB 2009, DOI: 10.1038/sj.bjp.0704230

  8. Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC-MS/MS using supported liquid extraction

    Biomedical Chromatography

    Volume 25, Issue 11, November 2011, Pages: 1245–1251, Yu Li, Thomas Emm and Swamy Yeleswaram

    Version of Record online : 10 FEB 2011, DOI: 10.1002/bmc.1597

  9. You have full text access to this OnlineOpen article
    Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase

    British Journal of Pharmacology

    Volume 171, Issue 24, December 2014, Pages: 5870–5880, J P Fry, K Y Li, A J Devall, S Cockcroft, J W Honour and T A Lovick

    Version of Record online : 24 NOV 2014, DOI: 10.1111/bph.12891

  10. You have free access to this content
    Influence of CYP2C9, 2C19 and 2D6 Genetic Polymorphisms on the Steady-State Plasma Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine

    Basic & Clinical Pharmacology & Toxicology

    Volume 97, Issue 5, November 2005, Pages: 296–301, Maria G. Scordo, Edoardo Spina, Marja-Liisa Dahl, Giuliana Gatti and Emilio Perucca

    Version of Record online : 18 OCT 2005, DOI: 10.1111/j.1742-7843.2005.pto_194.x

  11. Pharmacokinetics/Pharmacodynamics of Desloratadine and Fluoxetine in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 44, Issue 11, November 2004, Pages: 1252–1259, Dr Samir Gupta, Dr Christopher Banfield, Ms Bhavna Kantesaria, Mr Brian Flannery and Dr Jerry Herron

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270004269518

  12. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: Case study using the European risk assessment framework

    Integrated Environmental Assessment and Management

    Volume 6, Issue S1, July 2010, Pages: 524–539, Ken D Oakes, Anja Coors, Beate I Escher, Kathrin Fenner, Jeanne Garric, Marion Gust, Thomas Knacker, Anette Küster, Carola Kussatz, Chris D Metcalfe, Sara Monteiro, Thomas W Moon, Jan A Mennigen, Joanne Parrott, Alexandre RR Péry, Maria Ramil, Ines Roennefahrt, José V Tarazona, Paloma Sánchez-Argüello, Thomas A Ternes, Vance L Trudeau, Tatiana Boucard, Glen J Van Der Kraak and Mark R Servos

    Version of Record online : 1 APR 2010, DOI: 10.1002/ieam.77

  13. You have free access to this content
    Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine

    British Journal of Pharmacology

    Volume 144, Issue 6, March 2005, Pages: 821–829, Louise E Kennard, Justin R Chumbley, Kishani M Ranatunga, Stephanie J Armstrong, Emma L Veale and Alistair Mathie

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706068

  14. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

    Acta Psychiatrica Scandinavica

    Volume 103, Issue 1, January 2001, Pages: 66–72, M. Ferreri, F. Lavergne, I. Berlin, C. Payan and A. J. Puech

    Version of Record online : 7 JUL 2008, DOI: 10.1111/j.1600-0447.2001.00148.x

  15. You have free access to this content
    Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance

    British Journal of Clinical Pharmacology

    Volume 48, Issue 4, October 1999, Pages: 553–563, Brynne, Svanström, Åberg-Wistedt, Hallén and Bertilsson

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00051.x

  16. Laboratory persistence and fate of fluoxetine in aquatic environments

    Environmental Toxicology and Chemistry

    Volume 25, Issue 10, October 2006, Pages: 2561–2568, Jeong-Wook Kwon and Kevin L. Armbrust

    Version of Record online : 9 DEC 2009, DOI: 10.1897/05-613R.1

  17. Environmental occurrence and reproductive effects of the pharmaceutical fluoxetine in native freshwater mussels

    Environmental Toxicology and Chemistry

    Volume 29, Issue 6, June 2010, Pages: 1311–1318, Robert B. Bringolf, Rebecca M. Heltsley, Teresa J. Newton, Chris B. Eads, Stephen J. Fraley, Damian Shea and W. Gregory Cope

    Version of Record online : 24 FEB 2010, DOI: 10.1002/etc.157

  18. Fluoxetine Bioequivalence Study: Quantification of Fluoxetine and Norfluoxetine by Liquid Chromatography Coupled to Mass Spectrometry

    The Journal of Clinical Pharmacology

    Volume 39, Issue 10, October 1999, Pages: 1053–1061, M. O. Moraes, F. E. Lerner, G. Corso, F. A. Frota Bezerra, M.E.A. Moraes and G. De Nucci

    Version of Record online : 8 MAR 2013, DOI: 10.1177/00912709922011827

  19. Fluoxetine- and Norfluoxetine-Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 6, June 2014, Pages: 653–662, J E Sager, J D Lutz, R S Foti, C Davis, K L Kunze and N Isoherranen

    Version of Record online : 25 FEB 2014, DOI: 10.1038/clpt.2014.50

  20. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

    Clinical Pharmacology & Therapeutics

    Volume 51, Issue 3, March 1992, Pages: 239–248, Richard F Bergstrom, Albert L Peyton and Louis Lemberger

    Version of Record online : 27 MAR 1992, DOI: 10.1038/clpt.1992.18